was established in 2009 and officially listed in Hong Kong stocks on May 22, 2020. On August 21, Kintor Pharmaceutical announced its first-half results, which was the first "transcript" submitted after listing. There are three main highlights of this performance:
1. The commercialization of small molecule drugs: We plan to apply for the NDA listing of the first innovative drug prokruamide in the fourth quarter;
2. A breakthrough in macromolecules: We recently obtained dual-target antibody GS19 from Zejing, the second macromolecule project after obtaining ALK1 authorization from Pfizer;
3. The 20,000 square meters GMP plant will be officially put into operation this week.
In terms of financial data, the research and development expenses were 142 million yuan (excluding the salary of R&D personnel paid in the form of shares), an increase of 59% year-on-year, and the cash in hand was 1.79 billion yuan, mainly from IPO funds raised and bank credit. Capital expenditure is 33.03 million yuan.
From 11 am to 12 am on August 31st (Monday), Lu Yan, the chief financial officer of Kintor Pharmaceutical, will chat with Niu You online about Kintor Pharmaceutical's performance and follow-up plans. I hope you can speak freely. do not miss it!
1. How to participate:
Click the [Join Discussion] button below to post a question. Each question needs to be posted separately; questions with a high number of likes will have a higher chance of being answered.
2. Participation rules:
1. The content of questions must follow the community rules.
2. Futu does not intend to take responsibility for any investment behavior that relies on the company's reply.
3. Activity time:
August 31, 2020 11:00-12:00